Immune thrombocytopenia, severe hematological consequence in a patient with COVID‑19: A case report

Badulescu,Oana-Viola; Popescu,Diana; Ciocoiu,Manuela; Rezus,Ciprian

doi:10.3892/etm.2021.10475

Immune thrombocytopenia, severe hematological consequence in a patient with COVID‑19: A case report

Authors:
- Oana-Viola Badulescu
- Diana Popescu
- Manuela Ciocoiu
- Ciprian Rezus
View Affiliations

Affiliations: Department of Pathophysiology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, Department of Internal Medicine, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania
Published online on: July 21, 2021 https://doi.org/10.3892/etm.2021.10475
Article Number: 1043

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Since the first appearance of coronavirus disease 2019 (COVID‑19), multiple studies have focused on this novel coronavirus. Within a few months, the clinical and paraclinical manifestations and the mechanisms by which these changes are induced were elaborated. Clinically, the virus mainly causes the common cold, but can also result in severe or fatal pneumonia/acute respiratory syndrome. Regarding the biological changes, similar to any other virus, it can lead to a reduced lymphocyte count. The second most common change is represented by a reduced thrombocyte count. Furthermore, most patients have blood clotting abnormalities, inflammatory syndrome, raised D‑dimer and lactate dehydrogenase levels. Detection of immune thrombocytopenia in asymptomatic patients who tested positive for COVID‑19 justifies the need to perform differential diagnosis and testing for COVID‑19. Typically, patients with severe forms of COVID‑19 develop mild thrombocytopenia, while severe thrombocytopenia is rarely reported. The aim of this case report was to present the situation in which one asymptomatic patient who tested positive for COVID‑19 developed severe immune thrombocytopenia.

View Figures

View References

1	Xu P, Zhou Q and Xu J: Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 99:1205–1208. 2020.PubMed/NCBI View Article : Google Scholar
2	Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, Nguyen TT, Cao TM and Pham QD: Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med. 382:872–874. 2020.PubMed/NCBI View Article : Google Scholar
3	Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, et al: First case of 2019 novel coronavirus in the United States. N Engl J Med. 382:929–936. 2020.PubMed/NCBI View Article : Google Scholar
4	Chan JF, Yuan S, Kok KH, Wang KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, et al: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet. 395:514–523. 2020.PubMed/NCBI View Article : Google Scholar
5	Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou M, Drakoulis N, et al: A new threat from an old enemy: Re-emergence of coronavirus (Review). Int J Mol Med. 45:1631–1643. 2020.PubMed/NCBI View Article : Google Scholar
6	Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 365:507–513. 2020.PubMed/NCBI View Article : Google Scholar
7	Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 323:1061–1069. 2020.PubMed/NCBI View Article : Google Scholar
8	Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Lui L, Shan H, Lei CL, Hui DSC, et al: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382:1708–1720. 2020.PubMed/NCBI View Article : Google Scholar
9	Zhang Y, Zeng X, Jiao Y, Li Z, Liu Q, Ye J and Yang M: Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. Thromb Res. 193:110–115. 2020.PubMed/NCBI View Article : Google Scholar
10	Wool GD and Miller JL: The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 88:15–27. 2020.PubMed/NCBI View Article : Google Scholar
11	Liu Y, Sun W, Guo Y, Chen L, Zhang L, Zhao S, Long D and Yu L: Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study. Platelets. 31:490–496. 2020.PubMed/NCBI View Article : Google Scholar
12	Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F, Vinceti M, et al: Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med. 46:3–16. 2020.PubMed/NCBI View Article : Google Scholar
13	Martinic Z, Skopec B, Rener K, Mavric M, Vovko T, Jereb M and Lukic M: Severe immune thrombocytopenia in a critically ill COVID-19 patient. Int J Infect Dis. 99:269–271. 2020.PubMed/NCBI View Article : Google Scholar
14	Bao C, Tao X, Cui W, Yi B, Pan T, Young KH and Qian W: SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients. Exp Hematol Oncol. 9(16)2020.PubMed/NCBI View Article : Google Scholar
15	Bomhof G, Mutsaers PGNJ, Leebeek FWG, Te Boekhorst PAW, Hofland J, Croles FN and Jansen AJG: COVID-19-associated immune thrombocytopenia. Br J Haematol. 190:e61–e64. 2020.PubMed/NCBI View Article : Google Scholar
16	Humber S, Razanamahery J, Payet-Revest C, Bouiller K and Chirouze C: COVID-19 as a cause of immune thrombocytopenia. Med Mal Infect. 50:459–460. 2020.PubMed/NCBI View Article : Google Scholar
17	De la Cruz-Benito B, Rivas-Pollmar MI, Alvarez Roman MT, Trelles-Martinez R, Martin-Salces M, Lazaro-del Campo P, Ramirez-Lopez A, Garcia-Bacenilla S, Cebanu T, Acuna-Butta P, et al: Paradoxical effect of SARS-CoV-2 infection in patients with immune thrombocytopenia. Br J Haematol. 192:973–977. 2021.PubMed/NCBI View Article : Google Scholar
18	Maquet J, Lafaurie M, Sommet A and Moulis G: Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. Br J Haematol. 190:e276–e279. 2020.PubMed/NCBI View Article : Google Scholar
19	Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, Laffan M, Makris M, Newland AC, Provan D, Grainger JD and Hill QA: Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 189:1038–1043. 2020.PubMed/NCBI View Article : Google Scholar
20	Hu Z, Chen W, Liang W, Xu C, Sun W and Yi Y: Severe exacerbation of immune thrombocytopenia and COVID-19: The favorable response to corticosteroid-based therapy-a case report. Ann Hematol. 1–3. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print).
21	Mahevas M, Moulis G, Andres E, Riviere E, Garzano M, Crickx E, Guillotin V, Malphettes M, Galicier L, Noel N, et al: Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: A French multicentre series. Br J Haematol. 190:e224–e229. 2020.PubMed/NCBI View Article : Google Scholar
22	Bhattacharjee S and Banerjee M: Immune thrombocytopenia secondary to COVID-19: A systematic review. SN Compr Clin Med: Sep 19, 2020 (Epub ahead of print).